Claims
- 1. A compound of formula I: ##STR69## or stereoisomers or pharmaceutically acceptable salts thereof, wherein; one of D and D' is selected from CN, C(.dbd.NR.sup.7)NR.sup.8 R.sup.9, NHC(.dbd.NR.sup.7)NR.sup.8 R.sup.9, NR.sup.8 CH(.dbd.NR.sup.7), C(O)NR.sup.8 R.sup.9, and (CH.sub.2).sub.t NR.sup.8 R.sup.9 and the other is H;
- Z is selected from CH.sub.2, C.dbd.O, CH.sub.2 C(O), C(O)O, CONH, CH.sub.2 NH.sub.2, CH.sub.2 O, SO.sub.2, and SO.sub.2 NH;
- J.sup.1 and J.sup.2 are independently selected from O and CH.sub.2, provided that if J.sup.1 is O, then J.sup.2 is CH.sub.2 and if J.sup.2 is O, then J.sup.1 is CH.sub.2 ;
- R is selected from CO.sub.2 R.sup.1, COR.sup.1, OR.sup.1, NR.sup.2 R.sup.2a, CONR.sup.2 R.sup.2a, S(O).sub.p R.sup.1a, and S(O).sub.p NR.sup.2 R.sup.2a ;
- R.sup.a is selected from H and C.sub.1-4 alkyl;
- R.sup.b is H;
- when J.sup.1 and J.sup.2 are CH.sub.2, then R.sup.a and R.sup.b can combine to form a bond;
- R.sup.1 is selected from:
- H,
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3,
- C.sub.3-6 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- R.sup.1a is selected from:
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3,
- C.sub.3-6 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- R.sup.2 and R.sup.2a are independently selected from H, C.sub.1-4 alkyl, and phenyl;
- R.sup.2a may also be C.sub.1-4 alkoxy;
- R.sup.3 is selected from:
- phenyl substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- A is selected from:
- C.sub.3-13 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- B is selected from:
- X-Y, NR.sup.2 R.sup.2a, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, NR.sup.2 C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a,
- benzyl substituted with 0-2 R.sup.4a,
- C.sub.3-10 carbocyclic group substituted with 0-2 R.sup.4a, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- X is selected from C.sub.1-4 alkylene, --C(O)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --S(O).sub.p --, --S(O).sub.p CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S(O).sub.p --, --S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 --, --NR.sup.2 S(O).sub.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 NR.sup.2 --, --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, --C(O)NR.sup.2 CR.sup.2 R.sup.2a --, --NR.sup.2 C(O)CR.sup.2 R.sup.2a --, CR.sup.2 R.sup.2a C(O)NR.sup.2 --, --CR.sup.2 R.sup.2a NR.sup.2 C(O)--, --NR.sup.2 C(O)O--, --OC(O)NR.sup.2 --, --NR.sup.2 C(O)NR.sup.2 --, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a NR.sup.2 --, O, --CR.sup.2 R.sup.2a O--, --OCR.sup.2 R.sup.2a --, and S;
- Y is selected from:
- C.sub.3-10 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- R.sup.4 is selected from OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.1a, and CF.sub.3 ;
- R.sup.4a is selected from OH, halo, C.sub.1-4 alkyl, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.1a, and CF.sub.3 ;
- R.sup.5 is selected from:
- C.sub.3-10 carbocyclic group substituted with 0-2 R.sup.6, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.6 ;
- R.sup.6 is selected from H, OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl;
- R.sup.7 is selected from H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxy, C.sub.1-4 alkoxycarbonyl, C.sub.6-10 aryloxy, C.sub.6-10 aryloxycarbonyl, C.sub.6-10 arylmethylcarbonyl, C.sub.1-4 alkylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.6-10 arylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.1-6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C.sub.1-4 alkoxycarbonyl;
- R.sup.8 is selected from H, C.sub.1-6 alkyl and (CH.sub.2).sub.n -phenyl;
- R.sup.9 is selected from H, C.sub.1-6 alkyl and (CH.sub.2).sub.n -phenyl;
- n is selected from 0, 1, 2, and 3;
- m is selected from 0, 1, and 2;
- p is selected from 0, 1, and 2; and,
- r is selected from 0, 1, and 2.
- 2. A compound according to claim 1, wherein the compound is of formula Ia: ##STR70## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
- Z is selected from CH.sub.2, C.dbd.O, C(O)O, and SO.sub.2.
- 3. A compound according to claim 2, wherein;
- one of D and D' is C(.dbd.NR.sup.7)NH.sub.2 and the other is H;
- B is selected from:
- X-Y, NR.sup.2 R.sup.2a,
- benzyl substituted with 0-2 R.sup.4a,
- C.sub.3-10 carbocyclic group substituted with 0-2 R.sup.4a, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- X is selected from C.sub.1-4 alkylene, --C(O)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --S(O).sub.p --, --S(O).sub.p CR.sup.2 R.sup.2a --, CR.sup.2 R.sup.2a S(O).sub.p --, --S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 --, --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a NR.sup.2 --, O, --CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --;
- R.sup.4 is selected from OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, S(O).sub.p R.sup.1a, and CF.sub.3 ;
- R.sup.4a is selected from OH, halo, C.sub.1-4 alkyl, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, S(O).sub.p R.sup.1a, and CF.sub.3 ; and,
- n is selected from 0 and 1.
- 4. A compound according to claim 3, wherein the compound is of formula II: ##STR71## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
- R is selected from CO.sub.2 R.sup.1, COR.sup.1, OR.sup.1, CONR.sup.2 R.sup.2a, S(O).sub.p R.sup.1a, and S(O).sub.p NR.sup.2 R.sup.2a ;
- R.sup.1 and R.sup.1a are independently selected from:
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3,
- C.sub.3-6 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- X is selected from C.sub.1-4 alkylene, --C(O)--, --S(O).sub.p --, --NR.sup.2 --, and O; and,
- m is selected from 0 and 1.
- 5. A compound according to claim 4, wherein;
- R is selected from CO.sub.2 R.sup.1, COR.sup.1, OR.sup.1, and CONR.sup.2 R.sup.2a ;
- R.sup.1 and R.sup.1a are independently selected from:
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3, and
- C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4 ; and,
- R.sup.2 and R.sup.2a may be taken together to form a 5 or 6 membered ring substituted with 0-2 R.sup.4.
- 6. A compound according to claim 5, wherein;
- R.sup.a is selected from H and C.sub.1-4 alkyl;
- R.sup.1 and R.sup.1a are independently selected from C.sub.1-4 alkyl substituted with 0-1 R.sup.3 ;
- R.sup.3 is phenyl substituted with 0-2 R.sup.4 ; and,
- Y is a C.sub.3-10 carbocyclic residue substituted with 0-2 R.sup.4.
- 7. A compound according to claim 1, wherein the compound or pharmaceutically acceptable salt form thereof is selected from the group consisting of:
- trans-1-(4-amidinophenyl)methyl-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- (3S,4R)-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- (3R,4S)-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-(3-amidinophenyl)pyrrolidin-3-ylcarboxylic acid
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-(3-amidinophenyl)pyrrolidin-3-ylcarboxylic amide
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-(3-amidinophenyl)pyrrolidin-3-ylcarboxylic N,N-dimethylamide
- cis-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- cis-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-(3-amidinophenyl)pyrrolidin-3-ylcarboxylic acid
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carboisopropoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carbobutoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-acetyl-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-3-carboethoxy-3-methyl-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[[2-(2-cyanophenylthio)phenyl]carbonyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[[2-(2-cyanophenylthio)phenyl]methyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)sulfonyl)-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)sulfonyl]-3-carboisopropoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-1-[9-fluorenylmethoxycarbonyl]-3-carbomethoxy-4-(3-amidinophenyl)pyrrolidine;
- trans-2-benzyl-4-carbomethoxy-5-(3-amidinophenyl)isoxazolidine;
- trans-2-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-carbomethoxy-5-(3-amidinophenyl)isoxazolidine;
- trans-2-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-carboisopropoxy-5-(3-amidinophenyl)isoxazolidine; and,
- trans-2-[(2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methyl]-4-methoxymethyl-5-(3-amidinophenyl)isoxazolidine.
- 8. A compound according to claim 1, wherein the compound is of formula Ib: ##STR72## or a stereoisomer or pharmaceutically acceptable salt form thereof.
- 9. A compound according to claim 8, wherein;
- one of D and D' is C(.dbd.NR.sup.7)NH.sub.2 and the other is H;
- B is selected from:
- X-Y, NR.sup.2 R.sup.2a,
- benzyl substituted with 0-2 R.sup.4a,
- C.sub.3-10 carbocyclic group substituted with 0-2 R.sup.4a, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- X is selected from C.sub.1-4 alkylene, --C(O)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --C(O)O--, --OC(O)--, --S(O).sub.p --, --S(O).sub.p CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S(O).sub.p --, --S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 --, --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a NR.sup.2 --, O, --CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --;
- R.sup.4 is selected from OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, S(O).sub.p R.sup.1a, and CF.sub.3 ;
- R.sup.4a is selected from OH, halo, C.sub.1-4 alkyl, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2, NR.sup.2 C(O)R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, CH(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, S(O).sub.p R.sup.1a, and CF.sub.3 ; and,
- n is selected from 0 and 1.
- 10. A compound according to claim 9, wherein the compound is of formula IIa: ##STR73## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
- R is selected from CO.sub.2 R.sup.1, COR.sup.1, OR.sup.1, CONR.sup.2 R.sup.2a, S(O).sub.p R.sup.1a, and S(O).sub.p NR.sup.2 R.sup.2a ;
- R.sup.1 and R.sup.1a are independently selected from:
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3,
- C.sub.3-6 carbocyclic group substituted with 0-2 R.sup.4, and
- furanyl, isoxazolidinyl, pyranyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, tetrahydrofuranyl, and thienyl substituted with 0-2 R.sup.4 ;
- X is selected from C.sub.1-4 alkylene, --C(O)--, --S(O).sub.p --, --NR.sup.2 --, and O; and,
- m is selected from 0 and 1.
- 11. A compound according to claim 10, wherein;
- R is selected from CO.sub.2 R.sup.1, COR.sup.1, OR.sup.1, and CONR.sup.2 R.sup.2a ;
- R.sup.1 and R.sup.1a are independently selected from:
- C.sub.1-4 alkyl substituted with 0-1 R.sup.3, and
- C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4 ; and,
- R.sup.2 and R.sup.2a may be taken together to form a 5 or 6 membered ring substituted with 0-2 R.sup.4.
- 12. A compound according to claim 11, wherein;
- R.sup.1 and R.sup.1a are independently selected from C.sub.1-4 alkyl substituted with 0-1 R.sup.3 ;
- R.sup.3 is phenyl substituted with 0-2 R.sup.4 ; and,
- Y is a C.sub.3-10 carbocyclic residue substituted with 0-2 R.sup.4.
- 13. A compound according to claim 1, wherein the compound or pharmaceutically acceptable salt form thereof is selected from the group consisting of:
- trans-1-(methylsulfonyl)-3-([2'-aminosulfonyl-[1,1']-biphenyl-4-yl)aminocarbonyl)-4-(3-amidinophenyl)pyrrolidine;
- trans-1-(methylsulfonyl)-3-([2'-tert-butylaminosulfonyl-[1,1']-biphenyl-4-yl)aminocarbonyl)-4-(3-amidinophenyl)pyrrolidine;
- cis-1-(methylsulfonyl)-3-([2'-aminosulfonyl-[1,1']-biphenyl-4-yl)aminocarbonyl)-4-(3-amidinophenyl)pyrrolidine;
- trans-1-(methylsulfonyl)-3-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]-4-(3-amidinophenyl)pyrrolidine;
- trans-1-(methylsulfonyl)-3-[[5-(2'-tert-butylaminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]-4-(3-amidinophenyl)pyrrolidine;
- 1-(methylsulfonyl)-3-([2'-aminosulfonyl-[1,1']-biphenyl-4-yl)aminocarbonyl)-4-(3-amidinophenyl)-.DELTA..sup.3 -pyrroline;
- 1-(benzyl)-3-([2'-aminosulfonyl-[1,1']-biphenyl-4-yl)aminocarbonyl)-4-(3-amidinophenyl)-.DELTA..sup.3 -pyrroline; and
- trans-1-(methylsulfonyl)-3-([2'-aminosulfonyl-[1,1']-biphenyl-4-yl)methylcarbonyl)-4-(3-amidinophenyl)pyrrolidine.
- 14. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 15. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
- 16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 8 or a pharmaceutically acceptable salt thereof.
- 17. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 18. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
- 19. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 8 or a pharmaceutically acceptable salt thereof.
Parent Case Info
This application claims the benefit of U.S. Provisional Application No. 60/023,417, filed Aug. 16, 1996, and U.S. Provisional Application No. 60/033,436, filed Dec. 23, 1996.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5418233 |
Linz et al. |
May 1995 |
|
5463071 |
Himmelsbach et al. |
Oct 1995 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
2054850 |
May 1992 |
CAX |
9640679 |
Dec 1996 |
WOX |